Author of

• 25961

  +

  P3.07 - Nursing and Allied Professionals (Not CME Accredited Session) (ID 973)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27553

    +

    P3.07-13 - Non-Oncology Provider Immunotherapy Needs Assessment  (ID 12175)

    12:00 - 13:30  |  Presenting Author(s): Enza Nguyen
    • Abstract

    Background
    

    It is critical for non-oncology providers such as the emergency department, internal medicine, and critical care, to have accurate, up-to-date information on new cancer treatments such as immunotherapy (IO), and have means to properly identify immunotherapy-related adverse effects (IrAEs).

    IOs have a distinct side effect (SE) profile from standard cancer treatments such as surgery, chemotherapy and radiation therapy. With a subclass of IO are checkpoint inhibitors (CIs). Common CI SE are dermatologic toxicities such as pruritus and rash, experienced by half of patients receiving CIs (Davies, 2016). Gastrointestinal toxicities such as abdominal pain, nausea/diarrhea, can develop into colitis. The risk of intestinal perforation is high in patients with colitis from immunotherapy due to tissue damage from autoimmunity (Kroschinsky et al., 2017). Also, a cough and shortness of breath can advance into immune-mediated pneumonitis, which is most common in patients previously treated with surgery and radiation to the lungs (Doyle, 2016).

    In October 2017 IASLC released the first published guidelines, followed in February 2018 by the National Comprehensive Cancer Network guidelines. Through this project we are actively raising awareness and education of these guidelines at our community hospital.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A needs assessment survey was given to St. Joseph Hospital Emergency Care providers and Sepsis work group at their department staff meeting in 2017. In April 2018, this same survey was given to Hospitalists. A one page pre in-service survey was administered, followed a brief in-service, and a post in-service survey immediately followed. The Pre and post survey was used to evaluate effectiveness of teaching.

    Sample size: 30 non-oncology providers

    Data from 2017 and 2018 surveys will be collated to evaluate knowledge deficits, effectiveness of teaching, and implementation of IO patient identification card.

    Knowledge of IO SE management was measured with an identical pre and post in-service survey. The survey contained 5 items measuring the individual’s current knowledge/comfort with managing immunotherapy side effects for oncology patients receiving immunotherapy who are evaluated in St. Joseph Hospital.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Data analysis ongoing using SPSS- Preliminary results identified a gap.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The field of oncology and treatment of advance malignancies is growing at a fast pace, the oncology team will need to coordinate and educate other organ-specific specialties through educational programs and algorithms for the management of these AEs. Consequently, we need to assess the most constructive framework that can aid in the understanding and adoption of these newly published guidelines for the broader immune-oncology multidisciplinary team.

    6f8b794f3246b0c1e1780bb4d4d5dc53